50 results about "Triglyceride content" patented technology

The disclosure relates to a composition comprising a triglyceride component wherein: the triglyceride component comprises a mixture of triglycerides and wherein the mixture of triglycerides comprises individual triglycerides comprising one or more ester containing fatty acids and wherein the esters of the ester containing fatty acids are C8-C22 branched or straight chain fatty acid esters and wherein the composition has a drop melting point of between 30° and 70° C. and / or a combined monoglyceride and diglyceride content of between 0.5 and 10 percent.

The invention belongs to the field of microorganisms, and provides lactobacillus paracasei Jlus660321 with a function of assisting in reducing blood fat and cholesterol and application of the lactobacillus paracasei Jlus660321, and the preservation number of the lactobacillus paracasei Jlus660321 is CGMCC No. 33962. The lactobacillus paracasei Jlus 660321 has the functions of assisting in lowering blood fat and lowering cholesterol, shows excellent cholesterol lowering performance in a cholesterol degradation experiment, and can degrade 61.60% of cholesterol in the experiment. A hemolysis experiment result is gamma-hemolysis, namely, hemolysis is avoided, and toxic and side effects are small. Rat in-vivo experiments show that the lactobacillus paracasei Jlus 660321 can effectively slow down the increase of body weight, liver weight, liver index, low-density lipoprotein content and triglyceride content caused by high-fat diet, and further show that the lactobacillus paracasei Jlus 660321 has the function of assisting in reducing blood fat and cholesterol; the compound can be used for preparing medicines, nourishment or health care products for assisting in reducing blood fat and / or reducing cholesterol.

The present invention addresses the problem of providing: an oil or fat for chocolates, which has bloom resistance at a level similar to conventional CBE, and in which the change in viscosity in a tempering process is small; and a chocolate using the oil or fat.　The present invention preferably addresses the problem of further providing: an oil or fat for chocolates, which has good tempering properties under wide range of tempering conditions; and a chocolate using the oil or fat.　The problems can be solved by an oil or fat for chocolates, which satisfies all of requirements (A)-(D).　(A): The St2O triglyceride content is 10-50 wt%. (B): The ratio of the StStO triglyceride content to the St2O triglyceride content is at most 10 wt%. (C): The P2O triglyceride content is at least 3 wt%. (D): The ratio of the PPO triglyceride content to the P2O triglyceride content is at least 23 wt%.

The invention discloses hippophae rhamnoides polysaccharide with the activity of reducing blood sugar and blood fat as well as a preparation method and application thereof. Adding water into the degreased hippophae rhamnoides, adjusting the pH value to be acidic, then heating, stirring and extracting under an ultrasonic condition, and collecting filtrate; and performing post-treatment to obtain the sea-buckthorn polysaccharide. The content of neutral sugar in the sea buckthorn polysaccharide is 25.31%-30.68%, the content of uronic acid in the sea buckthorn polysaccharide is 54.66%-59.79%, and the content of protein in the sea buckthorn polysaccharide is 1.91%-2.14%. According to the method, the sea-buckthorn polysaccharide is extracted by adopting acid assistance-ultrasonic extraction, and the prepared sea-buckthorn polysaccharide has remarkable blood sugar and blood fat reducing activity. When the concentration of the sea-buckthorn polysaccharide is as low as 0.1 mg / mL, the glucose uptake of HepG2-IR cells can still be obviously improved, and the content of total cholesterol and total triglyceride of the HepG2-IR cells can be obviously reduced. The hippophae rhamnoides polysaccharide can be applied to preparation of food or medicine for reducing blood sugar and / or blood fat.

This invention relates to a method for rapidly screening filamentous fungi that produce high levels of triglycerides and polyunsaturated fatty acids, belonging to the field of microbial technology. The method employs a two-stage screening strategy of "resistance primary screening – fluorescence secondary screening." In the primary screening stage, strains with strong lipid synthesis capabilities are initially screened by adding a combination of phytocyanin and quizalofop-p-ethyl inhibitors to the culture medium. In the secondary screening stage, cellophane culture technology and Nile red fluorescence staining are combined to quantitatively assess the triglyceride content of the colonies, achieving rapid and non-destructive screening. This method is simple to operate, highly efficient, and shows a significant positive correlation between fluorescence intensity and triglyceride content. It is suitable for mutagenesis breeding and industrial strain selection of oil-producing filamentous fungi such as *Morchella alpineensis*.

The invention belongs to the technical field of microorganisms, and discloses clostridium butyricum ML5358 and application thereof.The clostridium butyricum ML5358 provided by the invention has the preservation number of CGMCC No.37000. The strain can effectively relieve mouse colitis induced by DSS and remarkably reduce expression of colon tissue inflammatory factors Il-6 and Il-1beta, and the preservation number of the clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. The clostridium butyricum ML5358 is CGMCC No.37000. In addition, skeletal muscle lipid metabolism can be regulated and controlled through the intestine-muscle axis, expression of fat synthesis and uptake related genes Srebf1, Acc1 and Fabp4 is specifically up-regulated, the content of intramuscular triglyceride is remarkably increased, and intramuscular fat deposition is promoted. According to the clostridium butyricum ML5358 and the application thereof, the functional limitation of traditional clostridium butyricum is broken through, and a new strain resource is provided for developing a novel microbial preparation or a feed additive capable of improving intestinal health and improving livestock and poultry meat quality.

The present invention discloses a N-oxalyl-D-phenylalanine compound and its ester prodrug, preparation method, pharmaceutical composition and application, wherein the N-oxalyl-D-phenylalanine compound is shown in the general formula (I). The present invention provides a series of highly selective and highly active FIH small molecule inhibitors and their prodrugs, which can selectively inhibit FIH activity and effectively reduce triglyceride content at the cellular and animal levels, and can be used to improve fat metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, and non-alcoholic fatty hepatitis. In addition, such FIH small molecule inhibitors are also expected to provide a molecular basis for the study of FIH molecular mechanism and pharmacological function, and to assist in the study of hypoxia response pathway regulation.

The invention provides a processing method of peanut butter, and belongs to the technical field of food processing. Peanut kernels are degreased through a hydraulic oil pressing device, the content of triglyceride in the peanut kernels is reduced, and product energy is reduced; in order to make up flavor loss caused by reduction of the grease content, enzyme and protease are adopted to conduct enzymolysis on degreased peanut kernels, the hydrolytic activity of protein and saccharides is improved, the content of free amino acid and reducing sugar is increased, and a flavor precursor is provided for Maillard reaction in the subsequent heat treatment process; the heat treatment can promote the generation of aroma substances and enable the flavor to be more harmonious; in order to ensure the quality of the peanut butter and improve the fluidity of the peanut butter, the crushed peanuts after heat treatment and the light-fat peanut oil are mixed and ground, so that the light-fat peanut oil is uniformly dispersed. Compared with traditional peanut triglyceride, the light-fat peanut oil has a lower metabolic energy value and good interfacial activity, not only can improve the rheological property, lubricity and structural stability of the peanut butter, but also can promote release and retention of flavor active substances.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The invention discloses a method for identifying or assisting in identifying the content of duck sebum triglyceride, a related composition and application, and belongs to the field of nucleic acid-containing determination methods. The method for identifying or assisting in identifying the content of the duck sebum triglyceride comprises the following steps: detecting the genotype of a specific SNP (Single Nucleotide Polymorphism) site of a duck to be detected, and identifying or assisting in identifying the content of the duck sebum triglyceride according to the genotype of the specific SNP site of the duck to be detected. The specific SNP site is an SNP site in a duck genome, the nucleotide type of the specific SNP site is T or C, and the specific SNP site is the 70th nucleotide of SEQ ID No.1. The method can be used for carrying out early selection on the multi-triglyceride content character of the duck sebum, so that the duck breeding efficiency is improved, and the breeding period is shortened.

The invention relates to the field of biological medicines, and discloses application of piperidine acid in preparation of a medicine for preventing and / or treating non-alcoholic steatohepatitis. The invention discovers that the piperidine acid can prevent and / or treat the non-alcoholic steatohepatitis for the first time. Specifically, non-targeted metabonomics detection finds that the content of the piperidine acid in an excrement sample of an NASH patient and a mouse model is reduced, and in-vivo experiments show that supplement of the piperidine acid can reduce the levels of ALT and AST in serum of an NASH mouse, reduce the content of triglyceride in the liver, and improve the expression of the NASH mouse. And the fat change, liver cell balloon-like change, inflammatory cell infiltration and fibrosis degree in the liver are improved in histology. In-vitro experiments show that piperidine acid can improve lipid deposition, inflammatory cell proliferation and fibrosis of liver organs. Moreover, the piperidine acid is an intestinal flora metabolite originally existing in a living body, and has no obvious toxicity to the living body; the oral administration is convenient and fast; commercial reagents are available and can be conveniently obtained.

The present invention addresses the problem of providing a water-in-oil emulsion which has a water separation suppression effect and a desired hardness even if the aqueous phase ratio is high and emulsifying agents other than lecithin and water-soluble dietary fibers are not substantially contained therein. The problem is solved by using a liquid fat or oil for water-in-oil emulsions, the liquid fat or oil having a specific constituent fatty acid composition, a diglyceride content and a triglyceride content within certain ranges, so as to provide a water-in-oil emulsion with a water separation suppression effect and a desired hardness.

A process for producing a triglyceride-phospholipid concentrate is provided, the process comprising: providing an egg yolk lecithin solution from the extraction of an egg yolk material with a liquid extractant, mixing the egg yolk lecithin solution with an OPO triglyceride carrier comprising 1,3-dioleoyl-2-palmitoylglycerol and having a ratio of palmitic acid in the 2-position of the triglycerides relative to the total palmitic acid in the triglycerides (SN2-C16:0) of at least 50%, and a C52 triglyceride content of at least 42 wt.%, and separating the liquid extractant from the mixture to produce a triglyceride- phospholipid concentrate comprising the OPO triglyceride carrier and egg lecithin.

The invention discloses an achilles tendon rupture risk assessment system, and belongs to the technical field of data processing systems. The achilles tendon rupture risk assessment system comprises a calculation unit and a result output unit which are sequentially connected on a data main path. A computer program is stored in the calculation unit; when the computer program is executed by the processor, a pi value calculation method is operated; the pi value is calculated according to the following formula I: # imgabs0 #, wherein e is a natural constant, and X1 is a dimensionless value of the height of the subject with cm as a dimension; x2 is a dimensionless value of the content of triglyceride with mmol / L as a dimension in the blood of the subject; x3 is a dimensionless value of the age of the subject with the age as the dimension; x4 is a dimensionless value of diastolic pressure of the subject in mmHg dimension; x5 is a dimensionless value of the content of fasting blood glucose with mmol / L as a dimension in the blood of the subject; x6 is the dimensionless value of the total cholesterol content of the blood of the subject with mmol / L as the dimension; x7 is a dimensionless numerical value of the body mass index of the subject with kg / m < 2 > as a dimension. The system and the method provided by the invention are comprehensive, effective and accurate in evaluation.

To provide an oil which does not become cloudy when stored at a low temperature while containing a specific amount of palmitic acid.SOLUTION: An oil containing a specific amount of palmitic acid has at least one characteristic selected from the group consisting of (i) a predetermined triglyceride content, (ii) a predetermined PUFA content, (iii) a predetermined stearic acid content, (iv) a predetermined content of C18 fatty acids, and (v) a predetermined DHA / EPA ratio. The oil does not become cloudy during low-temperature storage.SELECTED DRAWING: Figure 1

The invention provides a 5 alpha-reductase inhibitor. The inhibitor is pawpaw total triterpenes (TCS). The invention also provides application of the pawpaw total triterpenes TCS in preparation of drugs for treating benign prostatic hyperplasia. TCS and UA have no obvious toxic and side effects on visceral organs of each group of rats; the thickness of glandular epithelial cells in a TCS group is remarkably reduced, the 5AR activity of the TCS group is remarkably reduced, the T level is remarkably reduced, and the DTH level is remarkably reduced; the blood sugar of the TCS group is obviously reduced, the concentration of total cholesterol and low-density lipoprotein is obviously reduced, and the TCS can obviously increase the high-density lipoprotein level and reduce the content of triglyceride. The results show that the TCS and the main component tartaric acid have a remarkable inhibiting effect on prostatic hyperplasia. The inhibition of 5AR activity and the reduction of DHT generation and T content are one of the action mechanisms, and the important characteristic is that the prostatic hyperplasia can be inhibited and abnormal blood sugar and blood fat can be regulated at the same time.

The invention relates to the technical field of coreopsis tinctoria refined components and preparation and application, and provides a coreopsis tinctoria refined component and a preparation method and application thereof.The coreopsis tinctoria refined component comprises, by mass, 11 specific components of phenolic acids, flavonol, flavanol and flavonoid, and the 11 specific components comprise, by mass, 2 parts of gallic acid, 1 part of potassium sorbate, 1 part of potassium sorbate, 1 part of potassium sorbate and 1 part of potassium sorbate. The health-care food is prepared from the following raw materials in parts by weight: 3 parts of chlorogenic acid, 14 parts of quercetin, 18 parts of catechin, 5 parts of citric acid, 2-3 parts of procyanidine B, 3 parts of (+)-epicatechin, 1-31 parts of 31 parts of procyanidine C, 14 parts of rutin, 4 parts of camphanol-3-O-rutinoside and 2 parts of isorhamnetin-3-O-rutinoside. The snow chrysanthemum is Changbai Mountain snow chrysanthemum. Animal experiments show that the refined component can significantly reduce the content of total cholesterol and triglyceride in serum of a high-fat model rat, the specific component with blood fat regulating activity is prepared from Changbai Mountain snow chrysanthemum, and a new choice is provided for non-drug intervention of dyslipidemia.

This invention provides a method for quantitative analysis of intracellular lipid content based on the Bodipy 493 / 503 fluorescent probe, relating to the field of lipid metabolism detection technology. The method includes: (1) determining the absorption spectrum and excitation / emission spectrum of Bodipy 493 / 503 in isopropanol, and determining the maximum absorption wavelength and maximum excitation / emission wavelength of the fluorescent probe in isopropanol based on the spectral results; (2) staining the target cells with the Bodipy 493 / 503 probe after treatment with the compound, observing the changes in fluorescence signal in the field of view before and after isopropanol extraction, and taking pictures; (3) measuring the absorbance and fluorescence intensity of the isopropanol extract, analyzing the experimental results, and comparing them with the results of triglyceride content detection. This quantitative method is simple, fast, sensitive, effective, and has good experimental controllability and repeatability. The analytical results obtained are consistent with those obtained using other lipid content analysis methods, and it can be of great application in the field of research on the lipid metabolism interference effects of chemicals or environmental pollutants.

The invention provides an application of Nr4a3 as a target spot in preparing and screening a medicine for treating a non-alcoholic fatty liver disease. Experiments prove that in the NAFLD pathogenesis process, Nr4a3 expression is increased in the liver. Through knockout of Nr4a3 expression, the levels of alanine transaminase (ALT) and aspartate transaminase (AST) in NAFLD mouse blood can be reduced, the content of triglyceride in liver tissue and the content of collagen in the liver are reduced, and immune cell infiltration in the liver tissue is reduced. The invention provides a new way and exploration direction for the treatment of the non-alcoholic fatty liver disease.

The present invention relates to the field of confectionary materials, more particular to an aerated fat-based confectionary material comprising a fat phase, a sweetener, and optionally water, wherein the fat phase is the continuous fat phase having a certain content of lauric acid, palmitic acid, and stearic acid as well as a certain content of triglycerides with a carbon number of 46 (CN46) and carbon number of 42 and 44 (CN42+CN44). The present invention moreover relates to a method of preparing said aerated fat-based confectionary material and the use thereof in confectionary products.

The invention discloses a method for predicting the quality of frying oil assisted by artificial intelligence, and belongs to the technical field of food quality detection. The method comprises the following steps: firstly, determining an oxidized triglyceride early warning threshold value through temperature-time-index three-dimensional modeling on the basis of relevance between the oxidized triglyceride content and physicochemical indexes such as acid value, polar substances and peroxide value in a grease frying process; secondly, a layered random forest prediction model is constructed based on multi-factor and multi-index relation analysis, the first layer predicts the oxidized triglyceride content based on the frying temperature, time and fatty acid composition, and the second layer synchronously outputs an acid value, a peroxide value and a polar component in combination with an oxidized triglyceride prediction value. The oxidation risk can be recognized in advance, the problems that traditional indexes are high in hysteresis quality and high in detection cost are solved, and early warning and accurate prediction of the oxidation degree of the frying oil are achieved.

The invention discloses an application of Synaptamide in the treatment of hyperlipemia, and relates to a medicine for treating hyperlipemia. In-vivo experiments are carried out in a hyperlipidemia mouse model fed with high-fat diet, and after treatment with Synaptamide, the content of plasma triglyceride is remarkably reduced, and the content of plasma cholesterol is remarkably reduced. Therefore, Synaptamide can be used as a medicine for treating hyperlipemia, it is found for the first time that Synaptamide can effectively reduce the content of triglyceride and cholesterol in blood, and the medicine can effectively prevent and control hyperlipemia so as to reduce the incidence rate of ASCVD, so that a new intervention means is provided for prevention and control of atherosclerosis and related cardiovascular and cerebrovascular diseases.

The invention discloses lactobacillus plantarum ZYT028 and application thereof, the strain is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M 20251257, and the lactobacillus plantarum ZYT028 has good acid cholate tolerance and intestinal colonization ability, can still keep high survival rate under the condition of pH 2.0, and can grow in an environment containing 1.0 g / L cholate. The ZYT028 strain can promote the generation of short-chain fatty acid and improve the imbalance of intestinal flora caused by high fat diet; in animal experiments, the content of serum total cholesterol and triglyceride can be remarkably reduced, excessive weight increase is inhibited, and good lipid-lowering and weight-regulating effects are shown. The strain disclosed by the invention can be widely applied to development of functional foods, health-care products, fermented dairy products and probiotic preparations, and is used for assisting in controlling body weight and improving blood lipid metabolism.

The present application belongs to the field of analytical chemistry and electrochemistry, and particularly relates to an electrochemical sensor, a preparation method and application thereof in detection of sweat triglyceride content. A wearable sensor is prepared based on C-ZIF-67 / KB nanocomposite material, the sensor realizes detection of sweat triglyceride for the first time, and it is verified that sweat triglyceride level has high correlation with blood triglyceride level (correlation coefficient is 0.813, n=35). Through verification of a commercial colorimetric analysis kit, the sensor obtains a high correlation coefficient of 0.853 in detection of sweat triglyceride, which shows excellent accuracy.

The present invention relates to an anti-obesity composition comprising an extract of Rosa rugosa flower buds as an active ingredient, and by virtue of comprising the extract, aims to provide a composition having excellent anti-obesity efficacy by exhibiting the effects of inhibiting fat accumulation, reducing triglyceride content, increasing the expression of adipose triglyceride lipase (ATGL) and AMP-activated protein kinase (AMPK) proteins, and decreasing the expression of G0S2 (G0 / G1 switch 2) and perilipin proteins.

Brassica oleracea vegetable powder or composition containing same for regulating metabolic syndrome The present invention relates to the use of Brassica oleracea vegetable powder for regulating metabolic syndrome or a metabolic syndrome-related disease, for reducing the cholesterol and triglyceride content in cells and achieving the effect of improving or preventing metabolic syndrome or a metabolic syndrome-related disease, by administering to an individual an effective amount of Brassica oleracea vegetable powder or a composition containing Brassica oleracea vegetable powder.

The invention relates to an application of cis-astaxanthin in preparation of a lipid-lowering product. The cis-astaxanthin is astaxanthin as shown in a formula (I) and / or astaxanthin as shown in a formula (II). Compared with all-trans-astaxanthin, the specific cis-astaxanthin disclosed by the invention has the advantage that the lipid-lowering activity of the cis-astaxanthin is obviously better. The specific cis-astaxanthin not only can reduce lipid accumulation, the content of triglyceride and the ratio of oleic acid to stearic acid, but also can reduce the content of large lipid droplets and total cholesterol. The specific cis-astaxanthin disclosed by the invention not only can inhibit weight gain, but also can prevent and treat fatty liver, inhibit liver injury induced by obesity and reduce adipocyte size.

The present invention describes a vegetable oil comprising a polyunsatured fatty acid having at least 20 carbon atoms (LC-PUFA), which oil has(a) an anisidine value (AnV) of less than 25;(b) a peroxide value (POV) of less than 10;(c) a triglyceride content of greater than 90%; and / or(d) an Oil Stability Index (OSI) of greater than 5 hours at 80° C.

Disclosed is a process for preparing a final fat composition and its use in e.g. enrobing applications. The process involves the use of a first and a second vegetable fat composition with high contents of specific triglycerides, such as StOSt and POP, and the careful reduction of undesirable triglycerides like tri-palmitic and tri-stearic. The resulting fat composition is particularly suitable for use as a cocoa butter equivalent in chocolate and confectionery products, especially for enrobing applications. The process involves either blending these two fat compositions in specific weight ratios and then reducing the content of tri-palmitic and tri-stearic triglycerides to achieve a final fat composition with a certain percentage of POP+StOSt triglycerides, or individually reducing the tri-stearic triglyceride content in the first vegetable fat composition and the tri-palmitic triglyceride content in the second, followed by blending to obtain the final composition. The resulting fat composition is particularly suitable for various applications such as confectionery enrobing and coating, and as a cocoa butter equivalent.

According to the invention, a virtual screening method based on molecular docking is adopted to obtain 14 Miao compounds with relatively strong binding capacity with a farnesol X receptor. A series of in-vitro experiments are carried out on 14 Miao compounds, including a farnesol X receptor agonistic activity experiment, detection of the cytotoxicity of the compounds by an MTT method, and testing of the influence of the compounds on the triglyceride level of free fatty acid induced HepG2 cells by a GPO-PAP method. Experimental results show that the 14 compounds all have obvious agonistic activity on farnesoid X receptors, and have no cytotoxicity on HepG2 cells and L02 cells. Particularly, the compound 1, the compound 2 and the compound 3 can obviously reduce the content of triglyceride in HepG2 cells with fatty degeneration. Experimental results show that the 14 compounds can be further developed into drugs for treating farnesoid X receptor mediated diseases such as non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis, cholestatic liver diseases, hepatic fibrosis and the like.